Novo Nordisk has introduced Awiqli (insulin icodec) in India, the world's first once-weekly basal insulin, reducing annual injections for diabetes patients from 365 to just 52.
Awiqli is expected to reduce injection burden
Jul 09, 2026
02:25 pm
What's the storyDanish pharmaceutical company Novo Nordisk has launched Awiqli, the world's first once-weekly basal insulin for adults with Type 1 and Type 2 diabetes.
The launch marks a major shift in diabetes management as it reduces the number of insulin injections from 365 a year to just one every week.
Novo Nordisk readies once-a-week insulin shot for Indian market
Novo Nordisk launches once-weekly basal insulin 'Awiqli' in India as diabetes rates increase
India gets Novo Nordisk's once-weekly insulin injection Awiqli for adults with diabetes
Novo Nordisk launches weekly insulin shot Awiqli in India
Once-a-week insulin launched in India, but doctors say it won't replace daily shots for all
Novo Nordisk India rolls-out a once-weekly basal insulin Awiqli
World’s first once-weekly insulin injection launched in India: Endocrinologist shares 7 things to know before switching
Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment…
Novo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly…
The injection replaces the need for a daily basal insulin injection with a once-a-week dose. This reduces the annual number of…
Novo Nordisk launches Awiqli, the world's first once-weekly insulin, in India to revolutionize diabetes management.
India now offers Awiqli, a new once-weekly basal insulin for diabetes patients. This drug reduces annual injections from 365 to…
The product will be imported from Denmark and is priced at ₹2611 for a 1 ml pen (700 insulin units)
